Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $5.6 billion.

  • Genmab A's Total Non-Current Liabilities rose 95046.9% to $5.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 billion, marking a year-over-year increase of 95046.9%. This contributed to the annual value of $5.6 billion for FY2025, which is 95046.9% up from last year.
  • Per Genmab A's latest filing, its Total Non-Current Liabilities stood at $5.6 billion for Q4 2025, which was up 95046.9% from $529.0 million recorded in Q3 2025.
  • Genmab A's 5-year Total Non-Current Liabilities high stood at $5.6 billion for Q4 2025, and its period low was $177.0 million during Q4 2023.
  • In the last 3 years, Genmab A's Total Non-Current Liabilities had a median value of $533.0 million in 2024 and averaged $1.3 billion.
  • Per our database at Business Quant, Genmab A's Total Non-Current Liabilities skyrocketed by 20112.99% in 2024 and then soared by 95046.9% in 2025.
  • Genmab A's Total Non-Current Liabilities (Quarter) stood at $177.0 million in 2023, then soared by 201.13% to $533.0 million in 2024, then surged by 950.47% to $5.6 billion in 2025.
  • Its Total Non-Current Liabilities stands at $5.6 billion for Q4 2025, versus $529.0 million for Q3 2025 and $533.0 million for Q2 2025.